All manuscripts
Publications CTL Cells G-Rex®100M G-Rex®10M G-Rex®500M

Accelerated Production of Antigen-specific T Cells for Preclinical and Clinical Applications Using Gas-permeable Rapid Expansion Cultureware (G-Rex®)

Published Journal Journal of Immunotherapy

Share
11 pages Accelerated Production of Antigen-specific T Cells for Preclinical and Clinical Applications Using Gas-permeable Rapid Expansion Cultureware (G-Rex) — Journal of Immunotherapy, 2010

Overview

Evaluates G-Rex® for expanding antigen-specific CTLs. G-Rex® supports 3-20 fold higher cell output than 24-well plates by improving gas exchange and allowing deeper media. The device simplifies manufacturing by reducing interventions and supports high-density culture of CTLs and CAR-T cells without compromising function

What this paper found

Gas-permeable G-Rex® cultureware increased the output of Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) compared with 24-well plates while cutting hands-on work. Activated CTLs seeded at 5 × 10^5 cells/cm² reached a median of 7.9 × 10^6/cm² after 3 days in the G-Rex®40 versus 1.8 × 10^6/cm² in plates, mainly through better cell survival rather than extra divisions. With an optimized feeder-to-CTL ratio, the 16-day process in G-Rex®40 then G-Rex®500 gave a median 6.5 × 10^8 cells, and splitting cultures extended growth to a median 5.07 × 10^9 cells by days 27 to 30. Phenotype, antigen specificity and cytolytic activity were unchanged. Producing 1 × 10^10 CTLs fell from about 60 days and 129 hours of technician time to 23 days and 3 hours.

Note: In vitro study with donor-derived cells; the authors note that the therapeutic significance of antigen-specific CTLs will depend on their effectiveness in the clinical setting.

This bioprocess optimization increased T-cell output while decreasing the complexity and cost of CTL manufacture, making cell therapy more accessible. — Juan F. Vera, Lara J. Brenner, Ulrike Gerdemann, Minhtran C. Ngo, Uluhan Sili, Hao Liu, John Wilson, Gianpietro Dotti, Helen E. Heslop, Ann M. Leen, Cliona M. Rooney, Journal of Immunotherapy

Study details

Authors
Juan F. Vera, Lara J. Brenner, Ulrike Gerdemann, Minhtran C. Ngo, Uluhan Sili, Hao Liu, John Wilson, Gianpietro Dotti, Helen E. Heslop, Ann M. Leen, Cliona M. Rooney
Institution
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA · The Methodist Hospital, Houston, TX, USA · Texas Children's Hospital, Houston, TX, USA · Wilson Wolf Manufacturing, MN, USA
Journal
Journal of Immunotherapy
Year
2010
PMID / PMC
PMID: 20445351 · PMC
G-Rex® model(s)
G-Rex®100M, G-Rex®10M, G-Rex®500M
Cell type(s)
CTL Cells
Application area
Infectious disease
Study phase
Preclinical

How G-Rex® was used

EBV-specific CTLs were initiated by seeding PBMCs at 1 × 10^6/cm² (10^7 cells in total) with irradiated EBV-LCLs at a 40:1 ratio in 30 mL of medium in a G-Rex®40 (10 cm²). On day 9, 1 × 10^7 responder T cells were transferred with 5 × 10^7 LCLs to a G-Rex®500 (100 cm²) in 200 mL of medium, IL-2 was added on day 13 and cells were harvested on day 16. Cultures were split among G-Rex®500 vessels once density exceeded 7 × 10^8 cells, continuing to days 27 to 30. The G-Rex®40 was also compared directly with 24-well plates for viability and cell division, and a G-Rex®2000 was evaluated for medium depth.

Explore related

Full citation

Vera JF, Brenner LJ, Gerdemann U, et al. Accelerated Production of Antigen-specific T Cells for Preclinical and Clinical Applications Using Gas-permeable Rapid Expansion Cultureware (G-Rex). J Immunother. 2010;33(3):305-315.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →